Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) shares traded 23.96% higher at $19.76 on Wall Street last session.
In accordance with the data, 11 analysts cover Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $28.00 and a low of $9.00, we find $22.00. Given the previous closing price of $15.94, this indicates a potential upside of 38.02 percent. DCPH stock price is now 24.48% away from the 50-day moving average and 40.11% away from the 200-day moving average. The market capitalization of the company currently stands at $1.30B.
It has been rated a hold by 3 analysts and a buy by 6. Brokers who have rated the stock have averaged $19.64 as their price target over the next twelve months.
With the price target maintained at $22, Guggenheim recently Upgraded its rating from Neutral to Buy for Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH). On August 29, 2022, Cowen recently initiated its ‘Outperform’ rating on the stock quoting a target price of $25, while ‘JMP Securities’ rates the stock as ‘Mkt Outperform’.
In other news, Sherman Matthew L, EVP & Chief Medical Officer sold 2,587 shares of the company’s stock on Oct 03. The stock was sold for $48,455 at an average price of $18.73. Upon completion of the transaction, the EVP & Chief Medical Officer now directly owns 74,297 shares in the company, valued at $1.47 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 16, EVP & Chief Medical Officer Sherman Matthew L sold 1,768 shares of the business’s stock. A total of $19,006 was realized by selling the stock at an average price of $10.75. This leaves the insider owning 76,884 shares of the company worth $1.52 million. Insiders disposed of 19,660 shares of company stock worth roughly $0.39 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DCPH stock. A new stake in Deciphera Pharmaceuticals Inc. shares was purchased by IKARIAN CAPITAL, LLC during the first quarter worth $9,727,000. HILLSDALE INVESTMENT MANAGEMENT INC. invested $6,430,000 in shares of DCPH during the first quarter. In the first quarter, PARKMAN HEALTHCARE PARTNERS LLC acquired a new stake in Deciphera Pharmaceuticals Inc. valued at approximately $5,965,000. PUBLIC SECTOR PENSION INVESTMENT BOARD acquired a new stake in DCPH for approximately $4,229,000. THRIVENT FINANCIAL FOR LUTHERANS purchased a new stake in DCPH valued at around $3,919,000 in the second quarter. In total, there are 201 active investors with 74.80% ownership of the company’s stock.
Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) opened at $17.31 on Wednesday. During the past 12 months, Deciphera Pharmaceuticals Inc. has had a low of $6.51 and a high of $20.88. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.60, and a quick ratio of 5.30. The fifty day moving average price for DCPH is $15.87 and a two-hundred day moving average price translates $14.10 for the stock.
The latest earnings results from Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.6, beating analysts’ expectations of -$0.66 by 0.06. This compares to -$1.37 EPS in the same period last year. The company reported revenue of $35.97 million for the quarter, compared to $23.22 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 54.93 percent. For the current quarter, analysts expect DCPH to generate $33.15M in revenue.
Deciphera Pharmaceuticals Inc.(DCPH) Company Profile
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.